Navigation Links
Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference

FREMONT, Calif., Feb. 23 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that the validation results of the company's SmartChip Real-Time PCR System will be presented at Cambridge Healthcare Institute's 16th International Molecular Medicine Tri-Conference. The data will be presented by WaferGen scientists and collaborative researchers from the University of Pittsburgh School of Medicine. The conference will be held February 25-27 at the Moscone North Convention Center in San Francisco.

    Details of the poster presentation are as follows:

    Title:   "High-Density, Nano-Volume SmartChip System for Real-Time Gene
              Expression Analysis"

    Time:     From 9:40 a.m. (PST) on Wednesday, February 25 until 4:00 p.m.
              (PST) on Thursday, February 26

    Summary:  An overview of the company's novel whole genome, high-throughput
              SmartChip Real-Time PCR System, as well as data related to the
              system's performance as demonstrated in ongoing alpha testing

WaferGen's SmartChip alpha testing program, which is being conducted at the University of Pittsburgh School of Medicine, involves the study of RNA isolated from lung tissue samples from healthy patients, as well as patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Researchers are screening these RNA samples with the SmartChip Real-Time PCR System in order to assess the platform's performance in conducting novel gene expression research.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for gene expression, genotyping, cell biology and stem cell research for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. SmartChip is being developed as the first whole genome, high throughput gene expression real-time polymerase chain reaction (PCR) platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research.

Forward-Looking Statements

This press release contains certain "forward-looking statements". Such statements include statements relating to the company's goals, plans and projections, anticipated results of research, performance, reliability and cost-effectiveness of the company's SmartChip and other systems, and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2007, and its subsequent Quarterly Reports on Form 10-Q filed with the SEC. Investors and security holders are urged to read this document free of charge on the SEC's web site at The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

     Vida Communication (on behalf of WaferGen)
     Tim Brons (media)

SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
2. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh
3. Recent Advances in Organic Chemistry Using Real-Time In Situ FTIR
4. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
5. Real-time observation of the DNA-repair mechanism
6. Better business decisions with real-time data
7. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
8. Enigma Signs Real-Time PCR Licences With Applera
9. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
10. Simbionix Releases Powerful New Learning Management System With Enhanced True Assessment System(TM)
11. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
Post Your Comments:
(Date:11/30/2015)... Dec. 1, 2015  An interventional radiology technique shows promise ... preliminary results of a study being presented today at the ... America (RSNA). --> ... decades by interventional radiologists as a way to stop bleeding ... as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... be presenting at the 8 th Annual LD ... PM PT. Dr. John N. Bonfiglio a ... the presentation and will join TapImmune management in meeting ...
(Date:11/30/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Board ... the Company welcomes Neil Woodford,s call for ... internet report on NW Bio.  The Company,s Board is ... stated, "We agree with Mr. Woodford that, at ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):